A FIRST-LINE STANDARD OF CARE FOR PATIENTS ACROSS A BROAD RANGE OF PERFORMANCE STATUS (KPS 70-100)1,6

ABRAXANE + gemcitabine NCCN Category 1 recommendation for Patients with Good PS and some patients with PS 2 (KPS >=70) ABRAXANE + gemcitabine NCCN Category 1 recommendation for Patients with Good PS and some patients with PS 2 (KPS >=70)
Albumin-bound paclitaxel (ABRAXANE) + gemcitabine as first-line therapy allows for a treatment plan with 5–FU-based second-line therapy12

  • aCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
  • bGood performance status for this regimen (AG) is defined as KPS ≥70, so some patients with an ECOG score of 2 may be eligible to receive this regimen (AG).
  • cAccording to the NCCN Chemotherapy Order Templates: Peer-reviewed statements of consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
  • The albumin-bound paclitaxel (ABRAXANE) phase III MPACT study enrolled patients with KPS ≥70.12
    Good performance status is defined as ECOG 0-1 with patent biliary stent and adequate nutritional intake.
    Please refer to the NCCN Guidelines for pancreatic cancer for a complete list of recommended treatment options.

YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL